AMS BioteQ focuses its research and development efforts on three key stages: “novel compound development,” “patent in research and development technology,” and “new drug research and development.” They prioritize developing products for the market of topical medicines where there are currently no new drugs or unmet needs. In just two years, they have multiple potential products in development. Currently, they are deepening their patent layout with the goal of becoming a leader in the Taiwanese and global markets for new antibiotics and inhibitors of emerging viruses.
AMS BioteQ Chairman, Dr. Yi-Ju Tsai, emphasized the crucial importance of having strong patents in the antimicrobial dressing market. They are actively pursuing patent protection for various indications and applying for patents in the United States, Japan, Taiwan, and China. Their focus is on enhancing the overall value of new drugs through ongoing patent layouts. AMS BioteQ has already completed the development of an advanced prototype of a novel antimicrobial dressing designed for diabetic foot ulcers, pressure ulcers, and infectious wounds. They are currently in the process of a patent application for this innovation. Whether in terms of “novel antibiotic raw materials and technology” or “novel dressing formulas,” AMS BioteQ has a comprehensive patent layout. They are not only collaborating with foreign dressing manufacturers through “technology licensing” and “raw material sales” but also developing an artificial intelligence-assisted system for “Wound Healing in Diabetic Foot Ulcers Application.” Furthermore, they plan to work closely with distribution partners to promote their products.
In the area of antibacterial drugs, the short-term plan involves further confirming the mechanism of action of FORMOSA-1117 against bacterial infections. In the medium term, there are plans to complete preclinical testing, including acute toxicity tests, subchronic toxicity tests, and allergy tests. Additionally, patent applications and international journal publications will be pursued to enhance the value of research outcomes. In the long term, there will be efforts to submit an Investigational New Drug (IND) application to increase the value of the research results. Active discussions with domestic and international pharmaceutical companies are also underway, aiming for profit in advance through licensing agreements.
YUAN-03 will continue to undergo testing for its effectiveness in inhibiting the new variants of the Alpha and Delta strains of the coronavirus. If the tests are successful, further animal trials will be conducted, and collaborations with well-known international pharmaceutical companies will be sought. The goal is to make substantial progress in the development of new drugs for COVID-19 by the end of this year. This will enable Taiwan and the world to better combat the threat posed by the variants of the virus and eliminate the threat of the pandemic with more effective new treatments.
In addition to ongoing research and testing of new antibiotics, AMS BioteQ is also in discussions with the Kaohsiung Medical University and its related teams regarding cooperation on COVID-19 virus antibody testing reagents. This collaboration aims to expand into various biotechnology market segments and enhance overall profitability. Dr. Yi-Ju Tsai stated that AMS BioteQ is currently in discussions with Professor Sheng-Fan Wang’s team from the Department of Medical Laboratory Science and Biotechnology at Kaohsiung Medical University. They are discussing the authorization of the “Construction Method of the ELISA Platform for Neutralizing Antibody Testing of the Novel Coronavirus (COVID-19)” and “Establishment and Optimization of Methods for Detecting Novel Coronavirus Spike IgG and IgM Antibodies,” which are used to measure antibody levels and the protective efficacy against new coronavirus variants (Alpha and Delta) after vaccination. He emphasized that the COVID-19 pandemic has persisted for nearly two years, and many experts believe that “coexistence with the virus” may become a trend. In this context, with the continuous emergence of global vaccines and treatment drugs, the development of reagents for testing vaccine antibody neutralization efficacy becomes a necessary endeavor for medical institutions and the public to respond to the evolving pandemic and safeguard health.
AMS BioteQ continues to enhance its research and development capabilities to reduce the risk of drug development failures. They are actively seeking technology transfer licensing from abroad and establishing cooperative development opportunities with international pharmaceutical or biotechnology companies. Dr. Yi-Ju Tsai stated that AMS BioteQ is currently in active discussions with international pharmaceutical companies to introduce funding through licensing agreements. This is aimed at establishing a value chain for segmented profitability. In terms of strategy, they will adopt a regional licensing approach, allowing international pharmaceutical companies to expand sales channels and generate stable operating capital through royalty fees.
Looking ahead, AMS BioteQ will continue to focus its research and development on “valuable indications,” continuously challenging the field of biotechnological innovation. They will pursue a dual-track approach, combining “global licensing business” with their operational strategy of “rooted in Taiwan, with a global outlook.” This aims to provide the best solutions for patients worldwide.